Image: Pexels | Written by: Medical Companion Travel Content Team
Original articles, please do not reprint without permission
Recently, several doses of HPV vaccination have been reported to be controversial, and the World Health Organization's Strategic Advisory Group on Immunization (SAGE) held a meeting to review the evidence for 1 dose of human papillomavirus (HPV) vaccination and concluded that a single dose of HPV vaccine can provide reliable protection and is comparable to the efficacy of 2 or 3 doses of vaccination regimens. Now the domestic HPV vaccine is difficult to make an appointment, does this indicate that only one injection is good, three injections are not necessary, and the protective effect is the same? Many people are confused, and then Xiaobian will take you to understand more information about hpv vaccines.
(Weibo heat map)
HPV vaccine age requirement for cervical cancer vaccination
The necessary cause of cervical cancer is persistent infection with human papilloma virus (HPV). The World Health Organization (WHO) recommends HPV vaccination for women over 9 years old, and 9 to 26 years old is considered the optimal age to be vaccinated, and many countries also define the age of vaccination between 9 and 26 years old.On July 18, 2016, the HPV divalent vaccine (HPV 16 and 18 types) Cervarix (R)) was approved by the China Food and Drug Administration (CFDA), which is suitable for women aged 9 to 25 years, using a 3-dose immunization program. The population's perception of HPV and the organizational form of vaccination are important factors influencing the successful implementation of hpv vaccination programs.
The development of HPV preventive vaccines is a milestone in cervical cancer prevention research
Cervical cancer is a common gynecological malignancy, and its incidence is the second highest among female malignancies. According to 2002 statistics, there are an estimated 490,000 new cases of cervical cancer worldwide, and more than 270,000 women have died from the disease. For more than half a century, humans have been trying to eliminate cervical cancer with Pap smears. Significant progress was made in the etiology of cervical cancer in the 1980s, clarifying the etiological link between human papillomavirus and cervical cancer. The success of hpvic preventive vaccine development is a milestone in cervical cancer prevention research, and the current early means of preventing cervical cancer are HPV vaccine and cervical cancer screening.
Hpv vaccine manufacturers currently have two domestic listed companies (two-valent manufacturers Wantai Biological, Watson Biological), and foreign companies are GlaxoSmithKline and Merck.
(Vaccine details)
Recently, there has been a lot of discussion on the Internet, "one needle and three needles", many netizens said that the WHO voice has just fallen, the pharmaceutical factories have burst out collectively, and some do not pay attention to martial virtue. There is no clinical data support, it is recommended to be vaccinated according to the vaccine instructions, the relevant professor pointed out that the World Health Organization's strategic expert group on immunization proposed that only one dose of HPV vaccine can produce the same immune effect as 2 to 3 doses. The findings are based on concerns about the slow introduction of HPV vaccine into immunization programmes and low overall population coverage, and based on the increasing incidence and mortality of cervical cancer, recommending this vaccination program can accelerate the goal of eliminating cervical cancer. At present, there are still certain difficulties in "one-shot vaccination", which is difficult to implement in the short term. In the future, the process of achieving vaccination for all women is relatively long, but the mainland still advocates the whole process of vaccination, increases the coverage rate of the group, reduces the probability of cervical cancer in the group, and hopes that the majority of women will be able to meet up.
Domestic experts recommend that the HPV vaccine be given three injections together
On April 16, Professor Wei Lihui, chairman of the Colposcopy and Cervical Cancer Pathology Branch of the Chinese Eugenics Science Association and honorary director of the Department of Obstetrics and Gynecology of Peking University, said in an interview with Securities Times that due to limited evidence, (only one dose of HPV vaccine) cannot be considered as the best practice for HPV vaccination, and more comprehensive research data need to be accumulated. Given the large population of the mainland and the high demand for HPV vaccines, the current vaccines cannot meet the vaccination needs of women on the mainland. In addition, the vaccination rate of girls aged 9 to 14 years who benefit the most from HPV vaccine is less than 2%, so we still advocate three doses of full vaccination; advocate early vaccination for adolescent girls; and advocate that vaccination is better than no vaccination.
According to the literature survey, the antibody levels of HPV-16 and HPV-18 in girls aged 9-14 years old after receiving 2 doses of vaccine are higher than those of adult women aged 18-45 years who receive 3 doses, and 3 doses can induce long-term immune response, which is valid for 66 months, which shows that the effect of three injections in China is more trustworthy.
Message
Hpv vaccine global popularity, but also for many women a kind of protection, whether it is a shot or three shots, as long as the effectiveness of the vaccine protection, as far as possible vaccination, many regions have been carried out free vaccination program for women of the right age, women who have not yet been vaccinated can improve their own protection, it is recommended that conditions permit, complete vaccination, I hope that the country can implement a free policy for women across the country, in the future to achieve enough to eliminate cervical cancer.
bibliography
QIAO Youlin. A milestone in cervical cancer prevention research[J]. Basic Medicine and Clinical Medicine,2006,26(12):1293-1295. DOI:10.3969/j.issn.1001-6325.2006.12.001.
LI Qin,LIU Chunrong,LI Jing. Current status of HPV cognition and application of preventive HPV vaccines in women aged 9-26 years old worldwide[J]. China Oncology,2017,26(3):161-169. DOI:10.11735/j.issn.1004-0242.2017.03.A001.
HE Mei,ZHAO Fanghui,HONG Ying3,et al. Cognitive investigation of HPV and vaccines among women and medical staff in urban areas[J]. Chinese Journal of Oncology,2011,20(7):483-488.